An economic downturn always has effects that reverberate across an industry, and perhaps one of the most visible reverberations is in the realm of personnel - more layoffs and less hiring a
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh